nucleotide-based therapeutic agents
DESCRIPTION
Nucleotide-based therapeutic agents. MAJOR DRAWBACKS OF ANTISENSE OLIGONUCLEOTIDES. Biologic instability. MAJOR DRAWBACKS OF ANTISENSE OLIGONUCLEOTIDES. Biologic instability Cellular targeting Uptake Efflux from endosomes. MAJOR DRAWBACKS OF ANTISENSE OLIGONUCLEOTIDES. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Nucleotide-based therapeutic agents](https://reader035.vdocument.in/reader035/viewer/2022062500/568151a6550346895dbfd513/html5/thumbnails/1.jpg)
![Page 2: Nucleotide-based therapeutic agents](https://reader035.vdocument.in/reader035/viewer/2022062500/568151a6550346895dbfd513/html5/thumbnails/2.jpg)
![Page 3: Nucleotide-based therapeutic agents](https://reader035.vdocument.in/reader035/viewer/2022062500/568151a6550346895dbfd513/html5/thumbnails/3.jpg)
![Page 4: Nucleotide-based therapeutic agents](https://reader035.vdocument.in/reader035/viewer/2022062500/568151a6550346895dbfd513/html5/thumbnails/4.jpg)
![Page 5: Nucleotide-based therapeutic agents](https://reader035.vdocument.in/reader035/viewer/2022062500/568151a6550346895dbfd513/html5/thumbnails/5.jpg)
![Page 6: Nucleotide-based therapeutic agents](https://reader035.vdocument.in/reader035/viewer/2022062500/568151a6550346895dbfd513/html5/thumbnails/6.jpg)
![Page 7: Nucleotide-based therapeutic agents](https://reader035.vdocument.in/reader035/viewer/2022062500/568151a6550346895dbfd513/html5/thumbnails/7.jpg)
![Page 8: Nucleotide-based therapeutic agents](https://reader035.vdocument.in/reader035/viewer/2022062500/568151a6550346895dbfd513/html5/thumbnails/8.jpg)
MAJOR DRAWBACKS OFANTISENSE OLIGONUCLEOTIDES
Biologic instability
![Page 9: Nucleotide-based therapeutic agents](https://reader035.vdocument.in/reader035/viewer/2022062500/568151a6550346895dbfd513/html5/thumbnails/9.jpg)
![Page 10: Nucleotide-based therapeutic agents](https://reader035.vdocument.in/reader035/viewer/2022062500/568151a6550346895dbfd513/html5/thumbnails/10.jpg)
![Page 11: Nucleotide-based therapeutic agents](https://reader035.vdocument.in/reader035/viewer/2022062500/568151a6550346895dbfd513/html5/thumbnails/11.jpg)
MAJOR DRAWBACKS OFANTISENSE OLIGONUCLEOTIDES
![Page 12: Nucleotide-based therapeutic agents](https://reader035.vdocument.in/reader035/viewer/2022062500/568151a6550346895dbfd513/html5/thumbnails/12.jpg)
![Page 13: Nucleotide-based therapeutic agents](https://reader035.vdocument.in/reader035/viewer/2022062500/568151a6550346895dbfd513/html5/thumbnails/13.jpg)
MAJOR DRAWBACKS OFANTISENSE OLIGONUCLEOTIDES
![Page 14: Nucleotide-based therapeutic agents](https://reader035.vdocument.in/reader035/viewer/2022062500/568151a6550346895dbfd513/html5/thumbnails/14.jpg)
![Page 15: Nucleotide-based therapeutic agents](https://reader035.vdocument.in/reader035/viewer/2022062500/568151a6550346895dbfd513/html5/thumbnails/15.jpg)
![Page 16: Nucleotide-based therapeutic agents](https://reader035.vdocument.in/reader035/viewer/2022062500/568151a6550346895dbfd513/html5/thumbnails/16.jpg)
![Page 17: Nucleotide-based therapeutic agents](https://reader035.vdocument.in/reader035/viewer/2022062500/568151a6550346895dbfd513/html5/thumbnails/17.jpg)
![Page 18: Nucleotide-based therapeutic agents](https://reader035.vdocument.in/reader035/viewer/2022062500/568151a6550346895dbfd513/html5/thumbnails/18.jpg)
![Page 19: Nucleotide-based therapeutic agents](https://reader035.vdocument.in/reader035/viewer/2022062500/568151a6550346895dbfd513/html5/thumbnails/19.jpg)
![Page 20: Nucleotide-based therapeutic agents](https://reader035.vdocument.in/reader035/viewer/2022062500/568151a6550346895dbfd513/html5/thumbnails/20.jpg)
![Page 21: Nucleotide-based therapeutic agents](https://reader035.vdocument.in/reader035/viewer/2022062500/568151a6550346895dbfd513/html5/thumbnails/21.jpg)
![Page 22: Nucleotide-based therapeutic agents](https://reader035.vdocument.in/reader035/viewer/2022062500/568151a6550346895dbfd513/html5/thumbnails/22.jpg)
![Page 23: Nucleotide-based therapeutic agents](https://reader035.vdocument.in/reader035/viewer/2022062500/568151a6550346895dbfd513/html5/thumbnails/23.jpg)
![Page 24: Nucleotide-based therapeutic agents](https://reader035.vdocument.in/reader035/viewer/2022062500/568151a6550346895dbfd513/html5/thumbnails/24.jpg)
![Page 25: Nucleotide-based therapeutic agents](https://reader035.vdocument.in/reader035/viewer/2022062500/568151a6550346895dbfd513/html5/thumbnails/25.jpg)
![Page 26: Nucleotide-based therapeutic agents](https://reader035.vdocument.in/reader035/viewer/2022062500/568151a6550346895dbfd513/html5/thumbnails/26.jpg)
![Page 27: Nucleotide-based therapeutic agents](https://reader035.vdocument.in/reader035/viewer/2022062500/568151a6550346895dbfd513/html5/thumbnails/27.jpg)
![Page 28: Nucleotide-based therapeutic agents](https://reader035.vdocument.in/reader035/viewer/2022062500/568151a6550346895dbfd513/html5/thumbnails/28.jpg)
![Page 29: Nucleotide-based therapeutic agents](https://reader035.vdocument.in/reader035/viewer/2022062500/568151a6550346895dbfd513/html5/thumbnails/29.jpg)
INIBIT GENE EXPRESSION
INIBIT PROTEIN FUNCTION
AS-ODN siRNA mAbs Small molecule inhibitors